upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must beESMO Members under the age of 40. Selection will be made by the the ESMO Immuno-Oncology Congress 2024 Scientific Committee on a competitive basis...
upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must beESMO Members under the age of 40. Selection will be made by the the ESMO Immuno-Oncology Congress 2024 Scientific Committee on a competitive basis...
The ESMO Immuno-Oncology Congress is a global meeting offering an advanced educational programme and the latest scientific developments in this promising field. From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities ...
Sep 2024, Barcelona Sep 2023, Online +3 more editions FrequencyAnnual Next edition likely in Sep 2025 Official Links WebsiteContacts Report Error Claim this event Online Editions ESMO Immuno-Oncology Cong...11 - 13 Dec 2024 43 Followers
home / conference / esmo-immuno-oncology-congress Content TypeNeoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC By Caroline Seymour January 6th 2024 Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following ...
ESMO-IO 欧洲肿瘤内科学会 免疫肿瘤学大会ESMO Immuno-Oncology Congress ESCC 食管鳞状细胞癌Esophageal Squamous Cell Carcinoma FL 滤泡性淋巴瘤 Follicular Lymphoma FTC 输卵管癌Fallopian Tube Cancer GC 胃癌 Gastric Cancer GMP Good Manufacturing Practice《药品生产质量管理规范》 ...
2024年9月18日,复宏汉霖(2696.HK)宣布,首个创新型单抗 H药 汉斯状®(斯鲁利单抗)、中美欧三地获批的曲妥珠单抗生物类似药汉曲优®的多项最新研究结果在2024欧洲肿瘤内科学会(ESMO)大会上以壁报形式展示。 H药 汉斯状®为复宏汉霖自主研发的重组人源化抗PD-1单抗注射液,也是全球首个获批一线治疗小细胞肺...
Shiran Sun, et al. Neoadjuvant chemotherapy plus tislelizumab followed by adjuvant tislelizumab for locoregionally advanced nasopharyngeal carcinoma (NPC): A single-arm, phase II trial. Presented at: ESMO Immuno-Oncology Congress 2022. Dec. 7-9, 2022. Abstract 154P....
近期,由上海市东方医院李进教授担任主要研究者的创新型抗HER2单抗HLX22联合汉曲优(HLX02,曲妥珠单抗,美国商品名:HERCESSI,欧洲商品名:Zercepac)和化疗用于一线治疗HER2阳性晚期或转移性胃/胃食管交界部(G/GEJ)癌的II期临床研究(HLX22-GC-201)结果相继于2024年欧洲肿瘤学会胃肠道肿瘤研讨会(ESMO GI)和Cell Press细...
ESMO Immuno-Oncology Cong... 11 - 13 Dec 2024 43 Followers Different Located Editions Berlin, Germany17 - 21 Oct 2025 Lugano, Switzerland20 - 22 Mar 2025 2 Followers Paris, France03 - 05 Mar 2025 75 Followers 4 more event Organizer Send Stall Book Request Queries about the event? Ask ...